In 1983, Congress passed the Orphan Drug Act. The goal was to facilitate the development of drugs and devices to treat rare diseases. Within the legislation was a provision to establish an Orphan Products Board (OPB). The board’s purpose was to orchestrate action between government regulatory bodies, pharmaceutical companies and advocacy groups.